华西证券：维持中国中免“增持”评级，业务经营有望持续向上。

Core Viewpoint - Huaxi Securities maintains an "overweight" rating on China National Pharmaceutical Group (China National Pharmaceutical), indicating a positive outlook for the company's business operations moving forward [1] Group 1 - The company's business operations are expected to continue on an upward trajectory, supported by strong market demand and strategic initiatives [1] - Recent financial performance shows resilience, with key metrics indicating growth potential in the upcoming quarters [1] - The overall industry environment remains favorable, contributing to the optimistic outlook for China National Pharmaceutical [1]